Tysabri Registry Monthly Reports And Patient Checklist Follow-Up Advised
Executive Summary
Biogen Idec should receive monthly reports from its Tysabri risk management patient registry on checklists filled out prior to infusion, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee recommended March 8
You may also be interested in...
Tysabri Out Of Remission; Returns With Updated Indication, Risk Management
The indication for Biogen Idec/Elan's re-approved multiple sclerosis therapy Tysabri (natalizumab) stops short of limiting it to use as a second-line therapy
Tysabri Out Of Remission; Returns With Updated Indication, Risk Management
The indication for Biogen Idec/Elan's re-approved multiple sclerosis therapy Tysabri (natalizumab) stops short of limiting it to use as a second-line therapy
Tysabri Return To Market With Expanded Indication Backed By Committee
Biogen Idec's Tysabri could return to market as early as April with an expanded indication following review by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on March 7-8